Background: Aducanumab (BIIB037) is a human mAb against aggregated Aβ peptide being investigated as a disease-modifying AD treatment. Objective: Present interim safety, Aβ reduction, and mini-mental state examination (MMSE) and Clinical Dementia Rating sum of boxes (CDR-sb) changes by disease stage and ApoE4 status. Methods: In this multicenter, double-blind, placebo-controlled, multipledose study (PRIME; NCT01677572), patients (age 50-90 years) had positive florbetapir (Amyvid) PET scan and met clinical criteria for prodromal AD or mild AD dementia. Necessary patient/IRB approvals were obtained. Patients received aducanumab or placebo once every 4 weeks for 52 weeks in 7 arms stratified by ApoE4 status. Interim analyses include results to Week 30 (all arms) and Week 54 (placebo, 1, 3, 10 mg/kg; data for 6 mg/kg not yet available). Results: 165 patients were randomized and dosed with placebo, 1, 3, 6, or 10 mg/kg aducanumab (65% ApoE4 carriers; 41% had prodromal AD). Incidence (MRI-based) of the most common AE, amyloidrelated imaging abnormalities (ARIA), was dose and ApoE4-statusdependent (ARIA-edema, ApoE4 carriers: 0%, 5%, 5%, 43%, 55%, for placebo, 1, 3, 6, 10 mg/kg aducanumab, respectively; ApoE4 noncarriers: 0%, 0%, 9%, 11%, 17%). Dose-and time-dependent brain Aβ reductions (standard uptake value ratio change) were observed, which were consistent across mild/prodromal and ApoE4 carrier/ non-carrier subgroups. Dose-dependent slowing of MMSE and CDRsb decline was observed at 1 year across disease stages/ApoE4 genotypes. Conclusions: Dose-and ApoE4-dependent ARIA was the main safety finding. Aducanumab reduced Aβ plaques and slowed MMSE/CDR-sb decline across clinical stages and ApoE genotypes. Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder and with no effective treatments or preventative measures, its prevalence is growing. PD is characterized by cognitive and movement symptoms associated with a loss of dopaminergic neurons, synaptic dysfunction, and the presence of Lewy bodies comprised of α-synuclein. Evidence shows that smaller aggregates, oligomers, may be more toxic. Moreover, we have found that oligomeric α-synuclein coexists with tau protein in disease in a possible toxic synergy, implicating tau oligomers as a therapeutic target for synucleinopathies. Objective: Evaluate the efficacy of a tau oligomer-specific antibody (TOMA) in a synucleinopathy mouse model. Materials and methods: We treated seven-month-old mice overexpressing A53T mutated α-synuclein intravenously with either TOMA, an antibody for all forms of tau-Tau-13, or a control IgG and wild-type mice with saline. We tested mice on a battery of behavioral tasks assessing memory and motor function. Following testing, half of the mice were sacrificed and tissue was collected for biochemical and immunological analysis. Remaining mice were aged to 12 months and tested again. Results: A53T mice treated with TOMA were protected from cognitive and motor deficits, while treating with Tau-13 appeared to exacerbate the phenotype. We found decreased levels of toxic tau oligomers in the brains of TOMA-treated mice. Importantly, levels of dopamine were elevated in TOMA-treated mice, as well as the synaptic protein, Synapsin I. Conclusion: Targeting tau oligomers is beneficial for a mouse model of synucleinopathy and may be a viable strategy for treating PD. Objetive: Study the economic cost of dementia in Chile, and its variation according to SES. Patients and methods: 391 informal primary caregivers fullfilled the RUD-Lite and a SES questionnaire. The cost is decomposed into direct medical costs (medical care, drugs, exams), direct social costs (social service, daycare) and indirect costs -mostly associated to informal care. The study was approved by the Ethical and Scientific Committee -SSMO. Result: Mean monthly cost per patient is 915 USD. Direct medical costs account for 20 per cent of the cost; direct social costs are 5 per cent of the total and indirect costs is 75 per cent of total cost. The mean monthly cost is inversely related to SES. The monthly cost for the high SES is 696 USD while for the low SES it's 1021 USD. Conclusion: Direct medical costs increase with the SES of patientsreflecting differences in purchasing power-, indirect costs are inversely related to SES and more than compensate differences in medical costs. In lower SES groups, informal care is mostly provided by female caregivers who are inactive in the labor market. Compared to other HIC countries, the averaged cost is lower (10980 versus 32865 USD) and the distribution of informal cost is higer (70% versus 40%), consistent with the absence of universal coverage of dementia and a coherent public health response.
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Conclusions:
We showed for the first time that systemic inflammation predicts FC in the DMN of aMCI and AD patients. Background: subjective memory complaints (SMC) may confer higher risk of developing Alzheimer's disease (AD) known for its spatial navigation impairment. Whether subjective spatial navigation complaints (SSNC) associate with objective impairment in SMC subjects is unknown. We analyzed relationship between SSNC and brain atrophy in SMC compared to aMCI patients and controls. Methods: after providing consent and study approval, consecutive patients with SMC (n = 61), aMCI (n = 60) and cognitively normal elderly (CN, n = 12) were recruited from memory clinic in Prague. All had neuropsychology, 1.5 T brain scan, APOE genotyping and SSNC questionnaire inquiring about spatial skills developed in house. Brain volumes and cortical thinning were calculated using Freesurfer. Spearman correlations between SSNC and imaging measures were assesssed at alpha = .05. Results: SMC patients scored worse on SSNC questionnaire than CN (p = .013), whereas aMCI patients did not (p = .14). aMCI patients had more atrophy in several regions including hippocampus, entorhinal, parahippocampal and precuneus cortex compared to CN and SMC. However, in SMC, SSNC scores correlated with smaller hippocampi (r Sp = -0.36, p b 0.001), while in aMCI -perhaps anosognostic to spatial difficulties -did not. SMC Ɛ4 carriers scored worse on SSNC than SMC Ɛ4 noncarriers (p = .04). SMC Ɛ4 carriers had cortical thinning in precuneus (p = .013) and parahippocampus (p = .034) compared to SMC Ɛ4 noncarriers. Results: Particularly SMC Ɛ4 carriers are characterized by subjective spatial navigation difficulties associated with atrophy in regions implicated in both spatial navigation and AD. Asking a specific question may be a useful screening tool for subjects at risk of AD and may guide further referral of such patients. Table 1 shows the clinical characteristics of the sample and the neuropsychological test comparison between the groups. Table 2 and 3 shows the correlation and regression analyses between the different cognitive domains measured by the ACE-R, the FAB and the 7 subscales of the T-ADLQ. Introduction: The behavioural variant of frontotemporal dementia (bvFTD) is a clinical syndrome characterized by an early and progressive deterioration of personality, social comportment and cognition (Rascovsky et al, 2011 ). An early detection of behavioural impairments in FTD is crucial to an accurate Early behavioural changes such as disinhibition, apathy, loss of empathy among others are some symptoms used to diagnose probable bvFTD. However, it is unknown how those first behavioural symptoms influence and modify progression and course of the disease. Methods: We evaluated the neuropsychological, clinical and neuroanatomical correlates of a sample of forty-three FTD patients organized according to its first symptoms. We also collected neuropsychological and imaging data on thirty-four healthy seniors to control the analyses observed in patients. 
